Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.
Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P, Duployez N, Tanguy-Schmidt A, Tamburini J, Maury S, Doré E, Himberlin C, Duclos C, Chevallier P, Rousselot P, Bonifacio M, Cavé H, Baruchel A, Dombret H, Soulier J, Landman-Parker J, Boissel N, Clappier E.
Tanasi I, et al. Among authors: baruchel a.
Blood. 2019 Oct 17;134(16):1351-1355. doi: 10.1182/blood.2019001244.
Blood. 2019.
PMID: 31434701
Free article.
Clinical Trial.
No abstract available.